Form 8-K ARVINAS, INC. For: Mar 11

Go back to Form 8-K ARVINAS, INC. For: Mar 11

Arvinas Inc. (ARVN) PT Lowered to $20 at BMO Capital

March 12, 2025 6:30 AM EDT

BMO Capital analyst Etzer Darout lowered the price target on Arvinas Inc. (NASDAQ: ARVN) to $20.00 (from $82.00) while maintaining a Outperform rating.

The analyst comments "ESR1 Mutants Only: Arvinas' VERITAC-2 data fails to show stat sig PFS benefit vepdeg vs. fulvestrant in wt patient... More

Arvinas Inc. (ARVN) PT Lowered to $10 at Citi

March 11, 2025 3:52 PM EDT

Citi analyst Yigal Nochomovitz lowered the price target on Arvinas Inc. (NASDAQ: ARVN) to $10.00 (from $19.00) while maintaining a Neutral rating.

The analyst comments "The failure of VERITAC-2 to meet the primary PFS endpoint in the ITT population, driven by the lack of... More